CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study is studying a drug combination as a possible treatment for endometrial cancer.The drugs involved in this study ...
Phase 2
Lake Success, New York, United States and 2 other locations
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer...
Phase 2
New York, New York, United States and 8 other locations
and Femara (letrozole) can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will al...
Phase 2
Morristown, New Jersey, United States and 1 other location
This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial...
Phase 2
New Brunswick, New Jersey, United States and 2 other locations
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...
Phase 1, Phase 2
New York, New York, United States and 20 other locations
letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...
Phase 2
New York, New York, United States and 28 other locations
study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial...
Phase 2
Englewood, New Jersey, United States and 20 other locations
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial c...
Phase 2
New York, New York, United States and 6 other locations
(ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial...
Phase 1, Phase 2
New York, New York, United States and 7 other locations
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...
Phase 2
New York, New York, United States and 65 other locations
Clinical trials
Research sites
Resources
Legal